Read More Analyst Ratings News Price Target Morgan Stanley Maintains Underweight on Genmab, Raises Price Target to $34 By Benzinga Newsdesk Today, 10:30 AM Morgan Stanley analyst Matthew Harrison maintains Genmab (NASDAQ:GMAB) with a Underweight and raises the price target from $31 to $34. GMAB
Read More Analyst Ratings Downgrades News Piper Sandler Downgrades Metromile to Neutral By Benzinga Newsdesk Today, 10:30 AM Piper Sandler analyst Arvind Ramnani downgrades Metromile (NASDAQ:MILE) from Overweight to Neutral. MILE
Read More News Navidea Biopharmaceuticals Announces Settlement Of Platinum Litigation; Receipt Of Noncompliance Notice From NYSE American By Benzinga Newsdesk Today, 10:30 AM Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced settlement NAVB
Read More Contracts General News Small Cap Sports Esports Technologies Obtains Access To UK Gaming License By Shivani Kumaresan Today, 10:30 AM Esports Technologies Inc (NASDAQ:EBET) has secured access to a UK gaming license through an operator services agreement signed along with the $75.9… ASPGF